Challenges and opportunities for the implementation of virological testing in resource-limited settings

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Roberts, Teri ^a   Bygrave, Helen ^a   Fajardo, Emmanuel ^a   Ford, Nathan ^a,b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anti retroviral therapy; Dried blood spots; Monitoring; Resource limited settings; Viral load; Virological

Indexed keywords

VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECENTRALIZATION; DEVELOPING COUNTRY; DNA CONTAMINATION; DRIED BLOOD SPOT TESTING; DRUG TREATMENT FAILURE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MONITORING; LABORATORY DEVICE; LABORATORY TEST; PATIENT COMPLIANCE; POINT OF CARE TESTING; PRIORITY JOURNAL; SOUTH AFRICA; VIROLOGICAL MONITORING; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; ZAMBIA; BLOOD; DESICCATION; DRUG MONITORING; ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; METHODOLOGY; REVIEW; VIROLOGY;

ANTI-HIV AGENTS; BLOOD; DESICCATION; DEVELOPING COUNTRIES; DRUG MONITORING; HIV; HIV INFECTIONS; HUMANS; SPECIMEN HANDLING; VIRAL LOAD;

EID: 84872858326     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17324     Document Type: Article

References (65)

1. Sigaloff KCE, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
2. Lynen L, Van Griensven J, Elliott J. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Curr Opin HIV AIDS. 2010;5:1-5.
3. Keiser O, Chi B, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS. 2011;25:1761-9.
4. UNAIDS, Médecins Sans Frontières. Speed up scale-up: strategies, tools and policies to get the best HIV treatment to more people sooner. Geneva: 78 Rue de Lausanne; 2012:1-23.
5. Chang LW, Harris J, Humphreys E. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Cochrane Database Syst Rev. 2011;(2):1-48. Published by John Wiley and Sons, Ltd., 111 River street Hoboken, NJ 07030-5774.
6. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JBT, Boyer S, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis. 2011;11:825-33.
7. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ. 2011;343:d6792.
8. Davies M-A, Boulle A, Eley B, Moultrie H, Technau K, Rabie H, et al. Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa Collaboration. Trop Med Int Health. 2011;16:1367-71.
9. Rewari BB, Bachani D, Rajasekaran S, Deshpande A, Chan PL, Srikantiah P. evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing. J Acquir Immune Defic Syndr. 2010;55:610-4.
10. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé J-L, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53:1283-90.
11. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9:e1001194.
12. Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, et al. Viremia copy-years predicts mortality among treatment-naive human immunodeficiency virus-infected patients initiating antiretroviral therapy. Clin Infect Dis. 2011;53:927-35.
13. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007;44:128-34.
14. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11:750-9.
15. Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, et al. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS. 2011;25:2183-8.
16. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Geneva: World Health Organization; 2010.
17. Maldonado F, Biot M, Roman F, Masquelier C, Anapenge M, Bastos R, et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg. 2009;103:607-12.
18. Moore DM, Awor A, Downing R, Kaplan J, Montaner JSG, Hancock J, et al. CD4+T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;49:477-84.
19. Orrell C, Kaplan R, Wood R, Bekker L-G. Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy. AIDS Res Treat. 2011;469127. how to cite this article http://www.hindawi.com/journals/art/2011/469127/cta/ "vol 2011, article ID 469127, 6 pages"
20. Ford N, Darder M, Spelman T, Maclean E, Mills E, Boulle A. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One. 2010;5:e10460.
21. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker L-G, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12:83-8.
22. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg. 2009;103: 601-6.
23. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679-87.
24. Kerschberger B, Boulle AM, Kranzer K, Hilderbrand K, Schomaker M, Coetzee D, et al. Viral load at 3 months after initiation of antiretroviral therapy is associated with better virological and treatment outcomes than at 6 months. International AIDS Conference abstract MOPE144 17-20 July 2011. Geneva: International AIDS Society; 2011.
25. Barth R, Aitken S, Tempelman H, Geelen SP, van Bussel E, Hoepelman A, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther. 2012;17:377-86.
26. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011;5:1-166.
27. Prosperi MCF, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 2011;66: 1886-96.
28. Hosseinipour M, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127-34.
29. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis. 2009;9:637-49.
30. Kanapathipillai R, McGuire M, Mogha R, Szumilin E, Heinzelmann A, Pujades-Rodriguez M. Benefit of viral load testing for confirmation of immunological failure in HIV patients treated in rural Malawi. Trop Med Int Health. 2011;16:1495-500.
31. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment- naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009;14:523-31.
32. Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, et al. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2010;11:519-29.
33. Oliveira R, Krauss M, Essama-Bibi S, Hofer C, Robert Harris D, Tiraboschi A, et al. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. Clin Infect Dis. 2010;51:1325-33.
34. Brown ER, Otieno P, Mbori-Ngacha DA, Farquhar C, Obimbo EM, Nduati R, et al. Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis. 2009;199:1292-300.
35. Reekie J, Gatell J, Yust I, Bakowska E, Rakhmanova A, Losso M, et al. Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. AIDS. 2011;25:2259-68.
36. Médecins Sans Frontières. MSF activity report. Geneva: 78 Rue de Lausanne; 2010:1-108.
37. Médecins Sans Frontières. Undetectable: how viral load monitoring can improve HIV treatment in developing countries. Geneva: 78 Rue de Lausanne; 2012:1-35.
38. Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis. 2010;201:S16-26.
39. Greig J, du Cros P, Klarkowski D, Mills C, Jørgensen S, Harrigan PR, et al. Viral load testing in a resource-limited setting: quality control is critical. J Int AIDS Soc. 2011;14:23.
40. Rouet F, Ménan H, Viljoen J, Ngo-Giang-Huong N, Mandaliya K, Valéa D, et al. In-house HIV-1 RNA real-time RT-PCR assays: principle, available tests and usefulness in developing countries. Expert Rev Mol Diagn. 2008;8:635-50.
41. Wang S, Xu F, Demirci U. Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv. 2010;28:770-81.
42. Johannessen A, Trøseid M, Calmy A. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. J Antimicrob Chemother. 2009;64:1126-9.
43. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: Towards Universal Access. Recommendations for a public health approach. Geneva: World Health Organization; 2010.
44. Erikstrup C, Kallestrup P, Zinyama-Gutsire RBL, Gomo E, Luneborg-Nielsen M, Gerstoft J, et al. p24 as a predictor of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr. 2008;48:345-9.
45. Hamers R, Smit P, Stevens W, Schuurman R. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009;14:619-29.
46. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, Kassim S, et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol. 2010;48: 3158-64.
47. Rouet F, Foulongne V, Viljoen J, Steegen K, Becquart P, Valéa D, et al. Comparison of the generic HIV viral load assay with the amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods. 2010;163:253-7.
48. Murtagh M: UNITAID HIV/AIDS diagnostic landscape. 2nd ed. Geneva: World Health Organisation, 20, avenue Appia; 2012.
49. Gershy-Damet G-M, Rotz P, Cross D, Belabbes EH, Cham F, Ndihokubwayo J-B, et al. The World Health Organization African region laboratory accreditation process: improving the quality of laboratory systems in the African region. Am J Clin Pathol. 2010;134:393-400.
50. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;6736:1-8.
51. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, et al. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS. 2011;25:807-12.
52. Diaw PA, Daneau G, Coly AA, Ndiaye BP, Wade D, Camara M, et al. Multisite evaluation of a point-of-care instrument for CD4 (T-cell enumeration using venous and finger-prick blood: the PIMA CD4. J Acquir Immune Defic Syndr. 2011;58:103-11.
53. Glencross D, Coetzee L, Faal M. Performance evaluation of the PimaTM point-of- care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc. 2012;15:3.
54. World Health Organization. Scaling up antiretroviral therapy in resourcelimited settings: treatment guidelines for a public health approach. 2003:1-67.
55. Reigadas S, Schrive MH, Aurillac-Lavignolle V, Fleury HJ. Quantitation of HIV-1 RNA in dried blood and plasma spots. J Virol Methods. 2009;161: 177-80.
56. Lilian RR, Bhowan K, Sherman GG. Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots. J Clin Virol. 2010;48:40-3.
57. Johannessen A. Quantification of HIV-1 RNA on dried blood spots. AIDS. 2010;24:475-6.
58. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, Delaporte E, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol. 2009;47:1107-18.
59. Viljoen J, Gampini S, Danaviah S, Valéa D, Pillay S, Kania D, et al. Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso. J Acquir Immune Defic Syndr. 2010;55:290-8.
60. Tilghman MW, Guerena DD, Licea A, Pé rez-Santiago J, Richman DD, et al. Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico. J Acquir Immune Defic Syndr. 2011;56:e70-4.
61. Smith DM, May SJ, Perez-Santiago J, Strain MC, Ignacio CC, Haubrich RH, et al. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS. 2009;23:2151-8.
62. van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, Smith D. Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. Clin Infect Dis. 2010;52:264-70.
63. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, de Wit TFR, Hill AM. Costeffectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS. 2012;26:1663-72.
64. World Health Organization, UNAIDS. The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. Geneva: 20, avenue Appia; 2011.
65. Nicol D. Navigating the molecular diagnostic patent landscape. Expert Opin Ther Pat. 2008;18:461-72.